1. Home
  2. BCV vs CHRS Comparison

BCV vs CHRS Comparison

Compare BCV & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bancroft Fund Ltd.

BCV

Bancroft Fund Ltd.

N/A

Current Price

$21.03

Market Cap

143.7M

Sector

Finance

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

N/A

Current Price

$0.77

Market Cap

159.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BCV
CHRS
Founded
1971
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
143.7M
159.1M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
BCV
CHRS
Price
$21.03
$0.77
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $7.75
AVG Volume (30 Days)
10.9K
★ 1.6M
Earning Date
01-01-0001
11-09-2026
Dividend Yield
★ 8.13%
N/A
EPS Growth
N/A
★ 472.00
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$44.19
Revenue Next Year
N/A
$65.06
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$21.06
$0.75
52 Week High
$27.33
$2.62

Technical Indicators

Market Signals
Indicator
BCV
CHRS
Relative Strength Index (RSI) 34.91 35.98
Support Level N/A N/A
Resistance Level $22.72 $1.53
Average True Range (ATR) 0.48 0.09
MACD -0.03 -0.02
Stochastic Oscillator 6.70 7.57

Price Performance

Historical Comparison
BCV
CHRS

About BCV Bancroft Fund Ltd.

Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: